Drug intelligence / Profile preview

adalimumab + methotrexate + vedolizumab

Development stage: Unknown
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous, Oral

Overview

A triple combination therapy consisting of vedolizumab (a gut-selective α4β7 integrin antagonist), adalimumab (a TNF inhibitor), and methotrexate (an immunosuppressant). This combination was studied in the EXPLORER trial for treating biologic-naïve patients with newly diagnosed, moderate to high-risk Crohn's disease. The regimen includes vedolizumab 300 mg IV on day 1, weeks 2 and 6, then every 8 weeks; adalimumab 160 mg SC on day 2, 80 mg at week 2, then 40 mg every 2 weeks; and methotrexate 15 mg orally weekly.

Targets

α4β7 (Integrin alpha-4 beta-7 heterodimer)DHFR (Dihydrofolate reductase)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on adalimumab + methotrexate + vedolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab + methotrexate + vedolizumab.

Explore the full profile